Evidence suggests these drugs may also have potential cardiovascular benefits, with studies indicating reduced cardiovascular risk among people with type 2 diabetes who use GLP-1 receptor agonists (9–12). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.